Celsion Corporation Ceo Dr. Lawrence Olanoff Interviewed By Wall Street Reporter
Columbia, MD November 3, 2005- Celsion Corporation (AMEX: CLN) today announced that Dr. Lawrence Olanoff, Chief Executive Officer, was interviewed by Wall Street Reporter earlier today.
In the interview, Dr. Olanoff elaborated on Celsion's transformation from a medical device company to biopharmaceutical company, solely focused on the development of drugs for the treatment of cancer. To access this interview, please visit Wall Street Reporter at http://www.wallstreetreporter.com.
Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, Massachusetts Institute of Technology, Harbor UCLA Medical Center, Montefiore Medical Center and Memorial Sloan-Kettering Cancer Center in New York City, Roswell Park Cancer Institute in Buffalo, New York, and Duke University. For more information on Celsion, visit our website: http://www.celsion.com.
Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.
For Further Information Contact:
Tony Deasey
Celsion Corporation
410.290.5390
tony@celsion.com
General Info:
Marilynn Meek
Financial Relations Board
212-827-3773
mmeek@financialrelationsboard.com
Investor Info:
Susan Garland
212-827-3775
sgarland@financialrelationsboard.com
